Which has higher earnings & valuation, AGMB or BMEA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Biomea Fusion N/A N/A -$61.80M -$0.29 N/A

Is AGMB or BMEA more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Biomea Fusion N/A -253.73% -97.91%

Does the media prefer AGMB or BMEA?

In the previous week, AgomAb Therapeutics had 4 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for AgomAb Therapeutics and 2 mentions for Biomea Fusion. AgomAb Therapeutics' average media sentiment score of 0.54 beat Biomea Fusion's score of 0.48 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, BMEA or RZLT?

Rezolute is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.29 N/A Rezolute N/A N/A -$77.59M -$0.76 N/A

Is BMEA or RZLT more profitable?

Rezolute's return on equity of -62.99% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -253.73% -97.91% Rezolute N/A -62.99% -57.94%

Does the media refer more to BMEA or RZLT?

In the previous week, Rezolute had 27 more articles in the media than Biomea Fusion. MarketBeat recorded 29 mentions for Rezolute and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.48 beat Rezolute's score of 0.44 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 2 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BMEA or CCCC?

In the previous week, Biomea Fusion had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for C4 Therapeutics. Biomea Fusion's average media sentiment score of 0.48 beat C4 Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CABA or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Biomea Fusion N/A N/A -$61.80M -$0.29 N/A

Is CABA or BMEA more profitable?

Cabaletta Bio's return on equity of -128.27% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Biomea Fusion N/A -253.73% -97.91%

Does the media refer more to CABA or BMEA?

In the previous week, Cabaletta Bio had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Cabaletta Bio and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.48 beat Cabaletta Bio's score of 0.34 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EBS or BMEA?

In the previous week, Emergent Biosolutions had 7 more articles in the media than Biomea Fusion. MarketBeat recorded 9 mentions for Emergent Biosolutions and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.48 beat Emergent Biosolutions' score of 0.41 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biomea Fusion (BMEA) Competitors

$1.30 +0.03 (+2.36%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$1.30 +0.00 (+0.31%)

As of 10/5/2026 07:57 PM Eastern

Compare

BMEA vs. AGMB, RZLT, CCCC, CABA, and EBS

Should you buy Biomea Fusion stock or one of its competitors? Biomea Fusion's main competitors and comparable companies include AgomAb Therapeutics (AGMB), Rezolute (RZLT), C4 Therapeutics (CCCC), Cabaletta Bio (CABA), and Emergent Biosolutions (EBS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biomea Fusion compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, AgomAb Therapeutics had 4 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for AgomAb Therapeutics and 2 mentions for Biomea Fusion. AgomAb Therapeutics' average media sentiment score of 0.54 beat Biomea Fusion's score of 0.48 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Biomea Fusion	N/A	-253.73%	-97.91%

AgomAb Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 331.53%. Biomea Fusion has a consensus target price of $9.00, indicating a potential upside of 592.31%. Given Biomea Fusion's higher probable upside, analysts plainly believe Biomea Fusion is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

96.7% of Biomea Fusion shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

AgomAb Therapeutics beats Biomea Fusion on 6 of the 10 factors compared between the two stocks.

How does Biomea Fusion compare to Rezolute?

Biomea Fusion (NASDAQ:BMEA) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Rezolute had 27 more articles in the media than Biomea Fusion. MarketBeat recorded 29 mentions for Rezolute and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.48 beat Rezolute's score of 0.44 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A

Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Biomea Fusion currently has a consensus target price of $9.00, suggesting a potential upside of 592.31%. Rezolute has a consensus target price of $10.44, suggesting a potential upside of 141.21%. Given Biomea Fusion's higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rezolute	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Rezolute's return on equity of -62.99% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-253.73%	-97.91%
Rezolute	N/A	-62.99%	-57.94%

Summary

Rezolute beats Biomea Fusion on 7 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to C4 Therapeutics?

Biomea Fusion (NASDAQ:BMEA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Biomea Fusion had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for C4 Therapeutics. Biomea Fusion's average media sentiment score of 0.48 beat C4 Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biomea Fusion has higher earnings, but lower revenue than C4 Therapeutics. Biomea Fusion is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A
C4 Therapeutics	$35.95M	10.23	-$104.99M	-$1.00	N/A

Biomea Fusion has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-253.73%	-97.91%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 3.07, suggesting that its share price is 207% more volatile than the broader market.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Biomea Fusion presently has a consensus price target of $9.00, suggesting a potential upside of 592.31%. C4 Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 134.11%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities analysts plainly believe Biomea Fusion is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Biomea Fusion beats C4 Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Biomea Fusion is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

96.7% of Biomea Fusion shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cabaletta Bio had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Cabaletta Bio and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.48 beat Cabaletta Bio's score of 0.34 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cabaletta Bio's return on equity of -128.27% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Biomea Fusion	N/A	-253.73%	-97.91%

Cabaletta Bio currently has a consensus target price of $15.33, suggesting a potential upside of 637.18%. Biomea Fusion has a consensus target price of $9.00, suggesting a potential upside of 592.31%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Cabaletta Bio is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cabaletta Bio has a beta of 3.48, suggesting that its stock price is 248% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market.

Summary

Cabaletta Bio beats Biomea Fusion on 8 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Emergent Biosolutions?

Emergent Biosolutions (NYSE:EBS) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Biomea Fusion has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Biomea Fusion	N/A	-253.73%	-97.91%

Emergent Biosolutions has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.50	$52.60M	-$3.55	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

In the previous week, Emergent Biosolutions had 7 more articles in the media than Biomea Fusion. MarketBeat recorded 9 mentions for Emergent Biosolutions and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.48 beat Emergent Biosolutions' score of 0.41 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, indicating that its stock price is 128% less volatile than the broader market.

Emergent Biosolutions currently has a consensus price target of $10.00, suggesting a potential upside of 38.10%. Biomea Fusion has a consensus price target of $9.00, suggesting a potential upside of 592.31%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Biomea Fusion beats Emergent Biosolutions on 8 of the 15 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMEA vs. The Competition

Export

Metric	Biomea Fusion	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$92.05M	$3.85B	$7.14B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	17.36%
P/E Ratio	-4.48	12.99	274.32	26.20
Price / Sales	N/A	1,294.29	609.24	88.33
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	3.10	17.06	11.23	6.40
Net Income	-$61.80M	-$23.20M	$3.49B	$381.07M
7 Day Performance	3.17%	-2.14%	-1.31%	-0.28%
1 Month Performance	-35.96%	-10.22%	-5.97%	-4.51%
1 Year Performance	-51.31%	17.47%	7.26%	1.63%

Biomea Fusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMEA Biomea Fusion	2.0254 of 5 stars	$1.30 +2.4%	$9.00 +592.3%	-39.5%	$92.05M	N/A	N/A	37	Analyst Upgrade
AGMB AgomAb Therapeutics	3.5742 of 5 stars	$10.21 -2.9%	$37.50 +267.3%	N/A	$380.85M	N/A	N/A	62
RZLT Rezolute	3.2437 of 5 stars	$4.18 +7.2%	$10.00 +139.2%	-52.4%	$377.22M	N/A	N/A	71	News Coverage Analyst Upgrade Options Volume
CCCC C4 Therapeutics	1.2093 of 5 stars	$3.12 +4.7%	$7.00 +124.4%	+31.7%	$366.61M	$35.95M	N/A	104
CABA Cabaletta Bio	3.0008 of 5 stars	$2.00 -3.4%	$15.33 +666.7%	-14.8%	$350.96M	N/A	N/A	158	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMEA) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Competitors

BMEA vs. AGMB, RZLT, CCCC, CABA, and EBS

How does Biomea Fusion compare to AgomAb Therapeutics?

Summary

How does Biomea Fusion compare to Rezolute?

Summary

How does Biomea Fusion compare to C4 Therapeutics?

Summary

How does Biomea Fusion compare to Cabaletta Bio?

Summary

How does Biomea Fusion compare to Emergent Biosolutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomea Fusion (BMEA) Competitors

BMEA vs. AGMB, RZLT, CCCC, CABA, and EBS

How does Biomea Fusion compare to AgomAb Therapeutics?

Does the media prefer AGMB or BMEA?

Is AGMB or BMEA more profitable?

Do analysts rate AGMB or BMEA?

Which has higher earnings & valuation, AGMB or BMEA?

Do insiders and institutionals believe in AGMB or BMEA?

Summary

How does Biomea Fusion compare to Rezolute?

Do insiders & institutionals hold more shares of BMEA or RZLT?

Does the media refer more to BMEA or RZLT?

Which has better valuation & earnings, BMEA or RZLT?

Which has more volatility and risk, BMEA or RZLT?

Do analysts rate BMEA or RZLT?

Is BMEA or RZLT more profitable?

Summary

How does Biomea Fusion compare to C4 Therapeutics?

Does the media refer more to BMEA or CCCC?

Which has higher earnings and valuation, BMEA or CCCC?

Is BMEA or CCCC more profitable?

Which has more volatility & risk, BMEA or CCCC?

Do insiders and institutionals hold more shares of BMEA or CCCC?

Do analysts rate BMEA or CCCC?

Summary

How does Biomea Fusion compare to Cabaletta Bio?

Which has stronger valuation and earnings, CABA or BMEA?

Do institutionals & insiders hold more shares of CABA or BMEA?

Does the media refer more to CABA or BMEA?

Is CABA or BMEA more profitable?

Do analysts recommend CABA or BMEA?

Which has more risk and volatility, CABA or BMEA?

Summary

How does Biomea Fusion compare to Emergent Biosolutions?

Is EBS or BMEA more profitable?

Which has higher earnings and valuation, EBS or BMEA?

Does the media prefer EBS or BMEA?

Which has more volatility & risk, EBS or BMEA?

Do analysts prefer EBS or BMEA?

Do institutionals and insiders believe in EBS or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools